A surge in sophisticated phishing and social engineering attacks led to a staggering $370 million in cryptocurrency thefts this January, eclipsing losses from technical protocol hacks and signaling a dangerous shift in criminal tactics targeting individual users.
In a strategic reversal, GSK has handed back global rights to the clinical-stage RNA editing drug WVE-006 to Wave Life Sciences. Wave asserts the move allows it to faster advance the potential 'functional cure' for alpha-1 antitrypsin deficiency, while GSK refocuses on broader respiratory markets.
Tesla shares have surged nearly 40% in six months, driven by robotaxi and Optimus robot prospects. Now, swirling rumors of a potential merger with Elon Musk's SpaceX are adding rocket fuel to investor optimism, though analysts urge caution amid sky-high valuations.
The Rafah border crossing between Gaza and Egypt has partially reopened under the terms of the US-brokered ceasefire, permitting a limited number of medical evacuations for the first time in nearly two years, as tens of thousands await passage.
Despite posting strong quarterly earnings, Microsoft's stock suffered its worst single-day drop in years as Wall Street focused on soaring capital expenditures and a slight deceleration in cloud revenue growth, highlighting the intense pressure on tech giants to deliver immediate AI payoffs.
Investment firm Ashva Capital Management outlines its investment case for The Walt Disney Company in its Q4 2025 letter, highlighting the entertainment giant's enduring value proposition amid near-term market volatility.
Investment firm Giverny Capital highlights insurance distributor TWFG as a key holding in its latest letter, revealing a challenging year where its value-focused strategy lagged the AI-fueled market rally.
Investors in lighting specialist FW Thorpe have seen a negative total shareholder return of 25% since 2021, starkly underperforming the broader market's gains. Despite steady revenue growth, the share price decline highlights a disconnect with company fundamentals.
Despite a 14% share price decline over the past quarter, Associated British Foods (LON:ABF) demonstrates robust underlying financial health, driven by strong earnings growth and efficient capital reinvestment, suggesting potential for a market correction.
After a recent pullback, shares of French construction materials giant Saint-Gobain are trading at a notable discount to analyst targets. While long-term performance remains robust, investors are weighing near-term risks against potential value.
As the TSX rides a wave of broad-based earnings optimism, a closer look reveals smaller companies, often miscategorized as 'penny stocks', that combine financial resilience with clear growth trajectories. We examine three such firms with market caps up to CA$700 million.
With a commanding 84% institutional ownership, American Electric Power (AEP) finds its fate closely tied to major financial players. While such heavy institutional backing often signals stability, it also introduces unique market risks that retail investors should watch closely.
Bitcoin's sharp decline below critical technical levels has amplified fears of a prolonged bear market, with prominent critics questioning its fundamental value. While some analysts see a buying opportunity, the mood among traders is turning increasingly grim.
Fintech startup Jelou has raised $10 million in Series A funding to scale its AI-driven conversational banking platform, Brain, from Latin America to the U.S., enabling payments, verification, and credit services directly within messaging apps.
A massive document release related to Jeffrey Epstein has sparked outrage after failing to protect dozens of victims, publishing names and nude photos despite court-ordered redactions. The disclosure raises serious questions about procedural failures and victim protection.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Lithia Motors' shares have retreated over 11% in the past year, sparking debate among investors. A detailed analysis of its discounted cash flow and peer comparisons suggests the auto retailer may be significantly undervalued, trading at a steep discount to its estimated intrinsic value.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
The Qatar Investment Authority has backed a new $200 million fund by Shorooq Partners, aiming to inject institutional capital into the region's mature startups and bridge a critical funding hurdle on the path to public listings.
